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Healthy colonocytes derive 60 – 70% of their energy supply from short-chain fatty acids, particularly butyrate. Butyrate has
profound effects on differentiation, proliferation and apoptosis of colonic epithelial cells by regulating expression of various
genes associated with these processes. We have previously shown that butyrate is transported across the luminal membrane
of the colonic epithelium via a monocarboxylate transporter, MCT1. In this paper, using immunohistochemistry and in situ
hybridisation histochemistry, we have determined the profile of MCT1 protein and mRNA expression along the crypt to
surface axis of healthy human colonic tissue. There is a gradient of MCT1 protein expression in the apical membrane of the
cells along the crypt-surface axis rising to a peak in the surface epithelial cells. MCT1 mRNA is expressed along the crypt-
surface axis and is most abundant in cells lining the crypt. Analysis of healthy colonic tissues and carcinomas using
immunohistochemistry and Western blotting revealed a significant decline in the expression of MCT1 protein during transition
from normality to malignancy. This was reflected in a corresponding reduction in MCT1 mRNA expression, as measured by
Northern analysis. Carcinoma samples displaying reduced levels of MCT1 were found to express the high affinity glucose
transporter, GLUT1, suggesting that there is a switch from butyrate to glucose as an energy source in colonic epithelia during
transition to malignancy. The expression levels of MCT1 in association with GLUT1 could potentially be used as determinants
of the malignant state of colonic tissue.
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Colon cancer is a major cause of mortality in the industrialised
nations. It is resistant to most cytotoxic drugs, and success in
surgical resection depends largely on the absence of local and
distant metastases. The majority of colorectal cancers develop from
premalignant polyps, commonly referred to as adenomas (Muto et
al, 1975). The transition from normality to malignancy through the
adenoma-carcinoma sequence is characterised by an alteration in
the expression of a number of genes associated with the mainte-
nance of cellular homeostasis (Vogelstein et al, 1988). It is
increasingly evident that specific dietary factors have the potential
to influence the normal structure and function of the colon, and
various dietary components have been proposed as being either
beneficial or potentially harmful to colonic health (Lipkin et al,
1999). Epidemiological studies over the past 30 years have indi-
cated that a diet high in fibre and resistant starch can protect
against colon cancer (Burkitt, 1971; Kune et al, 1987).
Dietary fibre and resistant starch escaping hydrolysis in the small
intestine are fermented by colonic microflora to the short-chain
fatty acids (SCFA) acetate, propionate and butyrate (Macfarlane
and Cummings, 1991). Butyrate has an important role in maintain-
ing the health of the colonic mucosa (Treem et al, 1994; Bugaut
and Bentejac, 1993). It is the preferred metabolic fuel of the healthy
colonic epithelium, providing over 60% of the colonocytes’ energy
requirements (Cummings, 1984). In addition, it induces growth
inhibition and terminal differentiation in a variety of human colon
cancer cell lines (Kruh, 1982; Hague et al, 1995). These effects are
correlated with changes in the expression of various genes asso-
ciated with these processes (Archer et al, 1998; Siavoshian et al,
2000; Hague et al, 1997). In vivo studies have correlated butyrate
levels with a decreased incidence of colon cancer (Clausen et al,
1991), and butyrate instilled into the colonic lumen was shown
to reduce tumour development in a chemical model of colon carci-
nogenesis (Medina et al, 1988). Essential to these roles is the
absorption of butyrate across the colonic luminal membrane into
colonocytes. At the luminal pH of the human colon (pH 7), buty-
rate is present almost entirely in its anionic form (Phillips and
Devroede, 1979). This charged species is unable to cross the colo-
nocyte membrane by free diffusion, and therefore requires a
specific transport protein (Ritzhaupt et al, 1998a). We have
previously demonstrated that this carrier protein is the monocar-
boxylate transporter, MCT1 (Ritzhaupt et al, 1998b). MCT1 is a
member of the monocarboxylate transporter family, of which nine
isoforms have so far been identified (Halestrap and Price, 1999).
Under normal circumstances, glucose provides a small fraction
of the energy requirement of the colonic epithelium (Roediger,
1982). Glucose is absorbed from the blood across the basolateral
membrane of colonocytes via the low affinity glucose transporter
GLUT2 (Pinches et al, 1993), a member of the widely expressed
GLUT family of facilitative glucose transporters (Baldwin, 1993;
Shirazi-Beechey, 1995). It has been reported, however, that colorec-
tal cancers, in common with many other malignancies, have
enhanced glucose utilisation and glycolytic metabolism (Eigenbrodt
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et al, 1985; Holm et al, 1995). In many cases this increase in
glucose utilisation is often accompanied by expression of the high
affinity glucose transporter, GLUT1 (Yamamoto et al, 1990). GLUT
1 expression is normally confined to erythrocytes and cells at the
blood – brain interface, but is expressed by cells transformed with
ras or src oncogenes in culture (Flier et al, 1987) and by a number
of malignant cell types (Brown and Wahl, 1993; Nagase et al 1995;
Mellanen et al, 1994).
In this study we have used immunohistochemistry and in situ
hybridisation histochemistry to elucidate the pattern of expression
of the colonic butyrate transporter, MCT1, along the crypt – surface
axis. We report that the level of MCT1 mRNA and protein is
significantly reduced in colonic adenomas and carcinomas, with
the most dramatic decline observed in poorly differentiated carci-
nomas. We propose that a decline in the expression of MCT1
results in a reduction in the intracellular concentration of butyrate
required to regulate cellular homeostasis, and to be used as the
primary source of energy in the colonic epithelium. In the majority
of carcinomas studied, the suppression of MCT1 expression is
accompanied by the expression of the high affinity glucose trans-
porter, GLUT1 and a down-regulation of the low affinity glucose
transporter, GLUT2. We suggest that this rearrangement in gene
expression may provide the tumour cells with a growth advantage.
The levels of expression of MCT1 in association with GLUT1 and
GLUT2 could provide markers for improved diagnosis and tumour
classification. Furthermore, a better understanding of the underly-
ing mechanisms involved in the changes in nutrient transporter
gene expression could lead to the identification of potential thera-
peutic targets.
MATERIALS AND METHODS
Tissue samples
Tissue sections Paraffin embedded archival colonic tissue
sections from both male and female patients aged 54 – 84 years
were provided by the Royal Liverpool University Hospital Tissue
Bank. Sections were also prepared from biopsies obtained from
male and female patients (aged 53 – 82) undergoing colonoscopy.
Together they consisted of sections from 25 healthy colon samples,
20 histologically graded adenomas, and 30 carcinomas.
Resections and biopsies Segments of colonic tissues were
obtained from 10 male and female patients (aged 53 – 82) under-
going surgery for colon carcinomas. The histologically normal
boundaries were removed and designated as normal colonic tissue,
whilst the remainder were identified as carcinoma. Biopsy samples
were removed from various regions of the colon of 10 individuals,
aged 35 – 82, undergoing routine examinations. The biopsies were
shown to be histologically normal. After removal they were frozen
rapidly in liquid nitrogen and subsequently stored at 7808C until
use.
Approval was obtained from the Royal Liverpool and Broad-
green Hospitals Ethical Committee for the work presented in this
paper. Informed written consent was secured from all individuals
prior to removal of tissue.
Antibodies
The antibody to MCT1 was raised in rabbits against a peptide
(CQKDTEGGPKEEESPV) corresponding to the C-terminus
region of human MCT1, based on the procedure described by
Lachmann et al (1986). The GLUT1 antibody was a kind gift
from S Baldwin (University of Leeds, UK). The GLUT2 and
villin antibodies were from Biogenesis Ltd (UK) and The Binding
Site (UK), respectively. Polyclonal antibodies to rat/human
MCT2 and MCT4 were kindly provided by A Halestrap (Univer-
sity of Bristol, UK).
Peroxidase immunohistochemical detection of MCT1 and
GLUT1
Paraffin embedded sections (7 mm) were mounted on APES treated
slides, dewaxed and rehydrated through graded ethanol solutions.
The sections were microwaved in 1% ZnSO4 for 10 min and
allowed to cool, before endogenous peroxidase activity was
quenched by incubation in 0.3% hydrogen peroxide for 15 min.
Non-specific antibody binding sites were blocked by incubation
in 5% BSA for 1 h at room temperature. Primary antibodies were
added at the following concentrations diluted in PBS : MCT1,
1 : 100- 1 : 200 and GLUT1, 1 : 100. Sections were incubated at
48C overnight in a humid container, before being rinsed twice in
PBS. Horseradish peroxidase-conjugated anti-rabbit secondary
antibody (DAKO, UK) was added at a concentration of 1 : 200 in
PBS and incubation carried out at 258C for 1 h in a humid
container. Sections were incubated in DAB solution (0.5 mg ml71)
for 10 min in the dark and counterstained with Haematoxylin
Mayer (Raymond Lamb, UK). Coverslips were mounted in D.P.X
(Raymond Lamb, UK) and the sections viewed and photographed.
In situ hybridisation histochemistry
A plasmid (pGEM-T, Promega) containing a 545 bp cDNA frag-
ment of MCT1 (Ritzhaupt et al, 1998b) was linearised to provide
a template for subsequent in vitro transcription of both sense
and antisense cRNAs. Complementary RNA was prepared from
the linearised cDNA template using the DIG RNA labelling kit
(Roche), according to the manufacturer’s instructions. The labelled
cRNA was precipitated overnight and its integrity confirmed by
denaturing electrophoresis.
Tissue sections were de-waxed in 100% xylene before being
hydrated in graded ethanol solutions to ddH2O. Hydrated
sections were placed in 0.2 M HCl for 20 min, washed in
26SSC twice for 3 min and rinsed in 0.05 M Tris/HCl,
pH 7.4. Sections were incubated in proteinase K (1 – 15 mg ml71,
optimised for each sample) in an omnislide incubation chamber
(Hybaid, UK) at 378C for 1 h and rinsed twice in 0.2% glycine/
PBS. Post-fixation was carried out in 4% paraformaldehyde/PBS
for 4 min before the slides were rinsed in PBS and transferred
to 20% acetic acid for 45 s to block endogenous alkaline phos-
phatase activity. Sections were rinsed in 0.1 M triethanolamine
and immersed in freshly prepared 0.25% acetic anhydride,
0.1 M triethanolamine pH 8.0 for 10 min. At this stage, one slide
was incubated in RNase (20 mg ml71) at 378C for 1 h, with the
remaining slides maintained at room temperature in PBS.
Following RNase pretreatment, all the sections were rinsed in
ddH2O and incubated at 508C in pre-hybridisation solution
(50% formamide, 0.3 M NaCl, 20 mM Tris pH 8, 5 mM EDTA
pH 8, 10 mM DTT, 16Denhardt’s solution, 1 mg ml71 yeast
tRNA) for 1 h in an Omnislide chamber. Hybridisation solution
was added (50% formamide, 0.3 M NaCl, 20 mM Tris pH 8,
5 mM EDTA pH 8, 10 mM DTT, 16Denhardt’s solution,
1 mg ml71 yeast tRNA, 100 mg ml71 dextran sulphate,
200 ng ml71 DIG-labelled cRNA) and incubation at 508C
continued overnight. Following hybridisation the sections were
rinsed in 26SSC, 1 mM DTT at room temperature and trans-
ferred to 26SSC for 1 h. The slides were incubated at 508C
in wash buffer (0.3 M NaCl, 20 mM Tris/HCl pH 8, 1 mM EDTA,
1 mM DTT) overnight, washed in 26SSC for 30 min at room
temperature and transferred to 0.16SSC for 30 min. Non-speci-
fic protein binding sites were blocked by incubation in 0.5%
blocking buffer (Roche, UK) at room temperature for 30 min
before incubation with anti-DIG antibody (Roche, 1 : 500 in
blocking buffer) at room temperature for 2 h. Following incuba-
tion, the sections were incubated in detection buffer (100 mM
Tris-HCl pH 9.5, 100 mM NaCl, 50 mM MgCl2, 0.18 mg ml
71
BCIP, 0.34 mg ml71 NBT) and the reaction stopped when
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appropriate by immersion in ddH2O. The sections were counter-
stained with methyl green (0.5% (w v71), 15 s), air-dried and
coverslips mounted with Loctite UV adhesive.
Preparation of post-nuclear membrane fractions from
colonic biopsies
Human colonic tissue samples, 30 – 60 mg wet weight, from
healthy (control) and carcinoma were homogenised using a poly-
tron probe (6T microshaft, Ystral) with 500 ml of a buffer
(100 mM mannitol, 2 mM HEPES/Tris, pH 7.1). The probe was
washed with a further 250 ml of the same buffer, added to the
suspension, and centrifuged at 500 g for 10 min (Sorvall
RC5C). The supernatant was centrifuged at 30 000 g for 30 min
and the resultant pellet was resuspended in a buffer containing
300 mM mannitol, 20 mM HEPES/Tris, pH 7.4, 0.02% NaN3,
and made homogeneous with a Hamilton syringe. The protein
concentration of membranes was determined by its ability to
bind Coomassie blue according to the Bio-Rad assay technique
(Tarpey et al, 1995).
Western blotting
Assessment of MCT1 abundance The abundance of MCT1
protein in post-nuclear membrane samples was determined by
Western blotting as described previously (Dyer et al, 1997).
The protein components of colonic membranes (10 mg per lane)
were separated on 8% (w v71) polyacrylamide gels containing
0.1% (w v71) SDS and electrotransferred to nitrocellulose
membrane (Trans-blot, Biorad, UK). Non-specific protein bind-
ing sites were blocked by immersion of the nitrocellulose in
PBS-TM (PBS, 0.05% (v v71) Tween 20, 2% (w v71) non-fat
dry milk) for 1 h at room temperature. The nitrocellulose
membrane was incubated at room temperature for 1 h with
the antibody to MCT1 diluted 1 : 5000 in PBS-TM. Horseradish
peroxidase-conjugated anti-rabbit antibodies (Dako) were used
at a dilution of 1 : 2000. The specific immunoreactive band
(40 kDa) was blocked when the primary antibody was pre-incu-
bated with the immunising peptide. Immunoblots were
developed using the enhanced chemiluminescence (ECL) system
(Amersham International, UK) and exposed to Biomax-ML film
(Kodak). Band intensities were quantified by scanning densitome-
try (Phoretix 1D, Non-linear Dynamics).
Assessment of abundance of GLUT1, GLUT2 and villin The
nitrocellulose membrane used for Western blotting (see above) was
stripped of anti-MCT1 antibodies by washing 3610 min in an
acidic buffer (137 mM NaCl, 20 mM glycine/HCl pH 2.5; Dyer et
al, 1997). The membrane was rinsed in PBS containing 0.1 mM
EDTA and 0.5% (v v71) Triton X-100 (PBS-TE), and the samples
blotted for GLUT1 using a 1 : 2000 dilution in PBS-TE. The strip-
ping procedure was repeated after each blot and the samples
blotted for GLUT2 (1 : 2000 in PBS-TE) and villin using a mono-
clonal antibody to villin (1 : 1000 dilution in PBS-TE). Horseradish
peroxidase-conjugated anti-rabbit or anti-mouse secondary anti-
bodies (DAKO) were used at a dilution of 1 : 2000 in PBS-TE.
Specific immunoreactive bands for GLUT1 and GLUT2 (55 kDa)
were blocked when the antibodies were pre-incubated with their
respective immunising peptides. The immunoblots were developed
as described above.
Assessment of MCT2 and MCT4 protein levels The protein
components of colonic post nuclear membranes (20 mg per lane)
were separated on 8% (w v71) polyacrylamide gels containing
0.1% (w v71) SDS and electrotransferred to nitrocellulose
membrane (Trans-blot, Biorad, UK). Immunoblotting was carried
out as described above using antibodies to MCT2 and MCT4
(diluted 1 : 5000 and 1 : 1000 in PBS-TM, respectively).
Northern blotting
Total RNA was isolated from healthy biopsies or of paired normal
and carcinoma tissue samples (30 – 60 mg) using the RNeasy kit
(Qiagen) according to the manufacturer’s instructions. RNA
samples, 10 mg per lane, were separated on 1% (w v71) denaturing
agarose gels and transferred to nylon membrane (Duralon, Strata-
gene, UK) in the presence of 1.5 M sodium chloride and 0.15 M
sodium citrate (10 6 SSC). The RNA was fixed to the membranes
by UV light irradiation. RNA integrity and equality of loading/trans-
fer were assessed by methylene blue staining of the membranes. The
nylon membranes were pre-hybridised for 3 h at 428C with ULTRA-
hyb hybridisation solution (Ambion, UK) followed by hybridisation
for 16 h in the same buffer containing 16106 c.p.m. ml71 of the
appropriate cDNA probe labelled with [a-P32]dCTP using an Oligo-
labelling kit (Amersham Pharmacia Biotech). Subsequently, the
membranes were washed three times at 558C in a solution consisting
of 0.16SSC and 0.1% (w v71) SDS. The washed membranes were
exposed to Biomax-MS film (Kodak) for 24 h at 7808C and
subjected to autoradiography. The relative amounts of mRNA were
estimated by scanning densitometry of the autoradiograms (Phore-
tix ID quantifier, Non-linear Dynamics). The cDNA probes were as
follows: MCT1, 545 bp RT – PCR product from human colon (Ritz-
haupt et al, 1998b); GLUT1, 2.4 kb BamHI fragment (cDNA kindly
provided by S Baldwin, University of Leeds, UK); MCT2, 679 bp
RT – PCR product corresponding to nucleotides 731 – 1409 (Lin et
al, 1998); MCT4, 590 bp RT – PCR product corresponding to
nucleotides 174 – 763 (Price et al, 1998); 18S rRNA cDNA was a gift
from J Hesketh, University of Newcastle-upon-Tyne and a 1.4 kb
restriction product was used as a probe.
Statistics
Data are presented as means+s.e.m. of n samples. Comparisons
are made using the Student’s t-test.
RESULTS
Immunohistochemical detection of MCT1 in healthy
colonic epithelium
We have shown previously by immunoblotting that the butyrate
transporter, MCT1, is enriched 30-fold in the luminal membranes
isolated from healthy human colonic tissue compared to the cellu-
lar homogenate, indicating that the protein is predominantly
located on the luminal membrane of human colonocytes (Ritz-
haupt et al, 1998b). Here, using immunohistochemistry, we
sought to confirm and extend this observation to investigate the
pattern of MCT1 expression along the crypt-surface axis. Immuno-
histochemical detection of MCT1 using a horseradish peroxidase-
conjugated secondary antibody confirmed that MCT1 is predomi-
nantly located on the luminal membrane of healthy colonocytes
(Figure 1A,B). The signal was blocked by pre-incubation of the
antibody with the immunising peptide (Figure 1C). Immunodetec-
tion of villin, a marker of the colonocyte apical membrane,
revealed a similar cellular localisation (Figure 1D). The level of
expression of MCT1 was greatest on the luminal membrane of
epithelial cells on the surface of the colonic mucosa, and declined
rapidly with descent into the crypts (Figure 1A,B). At the base of
the crypts only very low levels of MCT1 protein were detected.
MCT1 is also present on the membranes of erythrocytes, contribut-
ing a degree of staining within the lamina propria.
Detection of MCT1 transcript in colonic epithelium by in
situ hybridisation histochemistry
We next sought to investigate the profile of expression of the
MCT1 transcript along the crypt-surface axis. In situ hybridisation
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histochemistry, using a DIG-labelled antisense probe specific for
MCT1, indicated that the MCT1 transcript is expressed along the
length of the crypt-surface axis (Figure 2A,B). Hybridisation of
the antisense probe with sections pre-incubated with RNase A
(Figure 2D) or untreated sections with the sense probe (Figure
2C) resulted in no detectable staining, indicating that the signal
was specific. Levels of the MCT1 transcript are significantly higher
than the protein levels detected at the base of the crypts, indicating
that the expression of the MCT1 mRNA precedes the MCT1
protein during cellular differentiation along the crypt-surface axis.
Immunohistochemical detection of MCT1 in healthy,
premalignant and malignant colonic tissue
Having established the profile of expression of the MCT1 transcript
and protein in healthy colonic tissue, we next investigated the
expression of MCT1 protein in sections of healthy colon, colonic
adenomas and carcinomas. Sections were prepared from wax-
embedded colonic tissues histologically graded as normal, tubular
adenoma, tubulo-villous adenoma, and carcinoma of varying
degrees of differentiation. A typical immunocytochemical analysis
of healthy colonic tissue using peroxidase labelling is presented
in Figure 3A. High levels of MCT1 were expressed in the epithe-
lium of all the healthy colon sections analysed. Of the adenoma
samples analysed, tubular adenomas, which are generally regarded
as having the lowest malignant potential, displayed the highest
levels of MCT1 expression (Figure 3C), although in the majority
of cases MCT1 abundance was still lower than in healthy colonic
tissue. Tubulo-villous adenomas were found to express MCT1 at
a much lower level than tubular adenomas, and the expression
was limited to discrete foci (Figure 3D). MCT1 expression was
significantly reduced in the majority of well-differentiated colonic
carcinomas (Figure 3E), and was barely detectable in all the poorly
differentiated colonic carcinomas analysed (Figure 3F). It should be
noted that, for comparative purposes, the high antibody titre used
(1 : 100, see Materials and Methods) resulted in cytoplasmic stain-
ing in the control samples expressing high levels of MCT1 (Figure
3A). The high antibody concentration was necessary to detect
negligible levels of MCT1 in the carcinoma samples analysed.
The data is summarised in Table 1.
Assessment of the levels of MCT1 protein and mRNA in
healthy and colonic carcinomas by Western and Northern
analyses
In order to assess quantitatively any potential changes in the
levels of MCT1 mRNA and protein during progression from
normality to malignancy, total RNA and post-nuclear membranes
were isolated from healthy and malignant colonic tissues and
analysed, by Northern and Western blotting respectively, for
MCT1 expression. The levels of MCT1 mRNA in healthy and
malignant colonic tissues were determined using Northern blot-
ting. As shown in Figure 4A (left panel), the levels of the
3.3 kb MCT1 transcript were significantly (68%+18,
P=50.001) reduced in the malignant tissue compared to the
paired healthy tissue following normalisation to 18S rRNA
controls. The expression of the 40 kDa MCT1 protein was found
to be 67%+15 (P=50.001) lower in carcinomas than in healthy
colonic tissue (Figure 4A, right panel) when normalised to villin
controls. The reduction in the level of MCT1 mRNA expression
was comparable with the decline in MCT1 protein levels shown
by Western blotting (Figure 4B).
Determination of the levels of MCT2 and MCT4 protein
and mRNA in colonic carcinoma
In healthy human colon, MCT2 is not expressed, whilst low levels
of MCT4 mRNA have been detected (Price et al, 1998). Functional
properties of MCT2 and MCT4 as elucidated by expression in
Xenopus oocytes have indicated that these MCT isoforms are able
to transport a range of monocarboxylates (Halestrap and Price,
1999).
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Figure 1 Immunohistochemical detection of MCT1 in healthy human
colon. Immunohistochemistry for MCT1 and villin was carried out on
healthy human colon biopsy sections using a peroxidase-conjugated sec-
ondary antibody as described in the Materials and Methods section.
MCT1 staining is seen as a brown colouring contrasting with the blue/pur-
ple counterstained nuclei. (A) MCT1, 6200 magnification; (B) MCT1,
6400 magnification; (C) MCT1 antibody pre-incubated with immunising
peptide, 6100 magnification; (D) immunodetection of villin, 6200 magni-
fication. Bars represent 50 mm.
A B
C D
Figure 2 Detection of MCT1 mRNA in healthy human colonic biopsy
sections by in situ hybridisation. In situ hybridisation was carried out on
healthy human colon biopsy sections using DIG labelled cRNA probes as
described in the Materials and Methods section. Sections were hybridised
with a specific antisense probe for MCT1 and the corresponding sense
probe to act as a control for non-specific binding. (A) MCT1 antisense
probe (6200); (B) MCT1 antisense probe (6400); (C) sense probe
(6200); (D) MCT1 antisense probe on RNase pre-treated sections
(6200). Specific staining is seen as a dark purple colour, contrasting with
the blue/green counterstained nuclei. Bars represent 50 mm.
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In colon carcinoma tissues MCT4 was expressed at the mRNA
level, as assessed by Northern blotting (see Figure 5). However,
the MCT4 protein was not detected using either Western blotting
(Figure 5) or immunocytochemistry. MCT2 was not expressed at
either the mRNA or protein levels.
Expression of GLUT isoforms in healthy and malignant
colonic tissue
Immunohistochemical analysis revealed that the majority (83.3%)
of colon carcinoma samples displaying low levels of MCT1
expressed GLUT1 at significant levels (Figure 6A). None of the
healthy colonic tissue samples displayed detectable epithelial
GLUT1 staining (Figure 6B). Staining of erythrocyte membranes
is visible in healthy sections (Figure 6B), acting as an internal
positive control. This data is summarised in Table 2. This finding
was reinforced by Western and Northern analyses, which indicated
significant levels of both GLUT1 protein and mRNA in carcinoma
samples displaying reduced MCT1 expression (Figure 6C). It is
notable that the levels of GLUT2 protein, the low affinity glucose
transporter normally expressed on the basolateral membrane of
healthy colonocytes, were hardly detectable in all of the carcino-
mas expressing GLUT1 (Figure 6C, right panel; n=6).
DISCUSSION
We have previously provided evidence that transport of butyrate
into the absorptive cells lining the lumen of the colon is predomi-
nantly mediated by the monocarboxylate transporter, MCT1
(Ritzhaupt et al, 1998b), and the expression of colonic MCT1 is
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Figure 3 Immunohistochemical detection of MCT1 in normal, adenoma
and carcinoma human colonic sections. Immunohistochemistry was carried
out on normal, adenoma and carcinoma human colonic tissue using a
horseradish peroxidase-conjugated secondary antibody as described in
the Materials and Methods section. MCT1 staining is seen as a brown col-
ouring contrasting with the blue/purple counterstained nuclei. (A) Healthy
human colon (6400); (B) healthy human colon with MCT1 antibody pre-
incubated with immunising peptide (6200); (C) tubular adenoma (6200);
(D) tubular-villous adenoma (6200); (E) well differentiated carcinoma
(6200); (F) poorly differentiated carcinoma (6200). Bars represent
50 mm. This data is summarised in Table 1.
Table 1 Summary of MCT1 protein levels assessed by immunohisto-
chemistry
Sample n High MCT1 (%) Low MCT1 (%)
Normal 25 24 (96) 1 (4)
Tubular adenoma 10 8 (80) 2 (20)
Tubular-villous adenoma 10 4 (40) 6 (60)
Adenocarcinoma 10 1 (10) 9 (90)
(well differentiated)
Adenocarcinoma 10 0 (0) 10 (100)
(moderately differentiated)
Adenocarcinoma 10 0 (0) 10 (100)
(poorly differentiated)
The abundance of MCT1 in healthy colon, colonic adenomas and colonic carcinomas
was graded according to the percentage of cells staining positively for MCT1. Staining
of erythrocytes was excluded. Whole sections were analysed and scored as high
MCT1 staining (450% of cells stained) or low MCT1 staining (550% of cells
stained) by an independent observer. Number of samples fitting criteria shown in
bold, percentage in parentheses. n=number of samples analysed.
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Figure 4 Assessment of MCT1 protein and mRNA levels in healthy co-
lon and colonic carcinomas by Western and Northern analyses. Post-nucle-
ar membranes and total RNA were isolated from normal and malignant
colon, and analysed for MCT1, villin and 18S rRNA abundance as described
in the Methods section. (A) Left panel: representative Northern blot show-
ing abundance of MCT1 in healthy and malignant colon. Nylon membranes
were stripped and reprobed for 18S rRNA to confirm equality of loading.
Right panel: representative Western blot showing abundance of MCT1 in
healthy and malignant colon. Nitrocellulose membranes were stripped
and re-probed for villin to confirm equality of loading. (B) Combined den-
sitometric analysis of Northern and Western blots displayed as a histogram.
MCT1 abundance in carcinomas (shaded square) is displayed relative to
healthy (solid square) where abundance in healthy samples=1. All values
are normalised to the corresponding 18S rRNA or villin signals. Error bars
represent+s.e.m. of 10 paired samples.
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tightly regulated by its substrate, butyrate (Cuff et al, 2002). In this
study we have sought to determine the in situ expression of MCT1
in the human colonic mucosa during the transition from normality
to malignancy. In the healthy colonic epithelium, the MCT1 protein
is primarily expressed on the apical membrane of colonocytes, with
the abundance of the protein being greatest in surface epithelial cells
and declining with descent into the crypts. The MCT1 transcript is
expressed homogeneously along the crypt-surface axis, and is
detectable in cells at the base of the crypts. A similar pattern of
expression of mRNA and protein along the crypt-surface axis has
been described for other intestinal nutrient transporters (Ramirez-
Lorca et al, 1999; Gallardo et al, 2001), and may reflect the process
of cellular differentiation from crypt to surface.
MCT1 protein abundance was significantly greater in healthy
colonic tissue than in any tissue representing different stages of
the adenoma – carcinoma sequence. Although lower levels of
MCT1 were detected in the majority of tubular adenomas analysed
than in healthy tissue, this level of expression was significantly high-
er than that seen in the majority of tubulo-villous adenomas
analysed. Tubulo-villous adenomas are regarded as having a greater
malignant potential than tubular adenomas (O’Brien et al, 1990),
and this may be reflected in the reduction in MCT1 expression.
The majority of carcinomas analysed exhibited very low levels of
MCT1; indeed the protein was barely detectable in all the poorly
differentiated carcinomas studied. It has been reported that
MCT2 and MCT4 have the potential to transport a range of mono-
carboxylates (Halestrap and Price, 1999). It has been shown that in
addition to MCT1, the high affinity pyruvate transporter MCT2 is
expressed at the mRNA level in neoplastic haematopoietic lineage
lines, Burkitt’s lymphoma Raji, and in solid tumour cell lines such
as SW480, A549 and G361 (Lin et al, 1998). The expression of
MCT2 protein, however, in these cell lines has not been assessed
(Lin et al, 1998), and therefore it is not evident if the mRNA is
translated into the corresponding protein. In order to determine
the potential presence of MCT2 and MCT4 in colon carcinoma,
the expression of these isoforms, at both mRNA and protein levels,
were assessed. Our results demonstrated that neither MCT2 nor
MCT4 proteins are expressed; although MCT4 mRNA was detected.
The antibodies to rat/human MCT2 and MCT4 however reacted
with specific proteins in the control rat liver and heart homogenate
samples, respectively. We conclude that MCT1 is the primary route
for transport of butyrate in the human colon (Ritzhaupt et al,
1998a,b; Cuff et al, 2002), and that its expression declines dramati-
cally during the transition from normality to malignancy.
The molecular mechanisms involved in the suppression of
MCT1 expression during the transition from normality to malig-
nancy are unknown. Work in our laboratory has shown that
expression of MCT1 is regulated by butyrate via transcriptional
and post-transcriptional mechanisms (Cuff et al, 2002). It has been
reported that levels of butyrate in the lumen of the colon in
patients with colorectal carcinomas is lower than in healthy indivi-
duals (Clausen et al, 1991). Whether the mechanism(s) involved in
down-regulation of MCT1 expression is (are) due to the reduced
substrate availability and/or the deregulation of intracellular events
involved in MCT1 regulation remain to be determined.
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Figure 5 Assessment of the expression of MCT2 and MCT 4 in colon
carcinoma measured by Western and Northern analyses. Post-nuclear
membranes and total RNA were isolated from malignant colonic tissues,
and analysed for MCT1, MCT2, MCT4, villin or 18S rRNA expression as
described in the Methods section. Left panel: representative Northern blot
showing abundance of MCT1 and MCT4 RNA in malignant colon. Nylon
membranes were stripped and re-probed for 18S rRNA to confirm equal-
ity of loading. Right panel: representative Western blot showing the levels
of MCT1 MCT2, and MCT4 proteins in malignant colon carcinoma tissues.
Nitrocellulose membranes were stripped and re-probed for villin to con-
firm equality of protein loading. Note: specific immunoreactive bands were
detected in control samples for MCT2 (in rat liver homogenate) and MCT4
(in rat heart tissue homogenate).
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Figure 6 Abundance of GLUT1 in healthy and diseased colon. Immuno-
histochemistry was carried out on healthy and malignant human colonic tis-
sue sections using a horseradish peroxidase conjugated secondary antibody
as described under ‘Methods’. GLUT1 staining is seen as a brown colour
contrasting with the blue/purple counterstained nuclei. (A) moderately dif-
ferentiated carcinoma (6200). Bars represent 50 mm. Pre-incubation of
antibody with immunising peptide resulted in absence of staining (data
not shown). (B) Healthy colon (6200). Significant erythrocyte staining
can be seen in the lamina propria. (C) Post-nuclear membranes and total
RNA were extracted from healthy (H) and carcinoma (C) tissues and ana-
lysed for MCT1, GLUT1 and GLUT2 mRNA and protein abundance as de-
scribed in ‘Methods’. Left panel: representative Northern blot indicating
levels of MCT1 and GLUT1 mRNA (n=6). Right panel: Representative
Western blot demonstrating levels of MCT1, GLUT1 and GLUT2 proteins
(n=6).
Table 2 Summary of GLUT1 immunohistochemistry data
Sample n GLUT1 negative (%) GLUT1 positive (%)
Normal 24 24 (100) 0 (0)
Carcinoma 24 4 (16.7) 20 (83.3)
Whole sections of healthy colon and colonic carcinomas were scored for GLUT1
staining as either positive (410% cells stained) or negative (510% cells stained)
by an independent observer. Erythrocyte staining was disregarded. Only carcinomas
displaying reduced levels of MCT1 staining were analysed. Number of samples fitting
criteria shown in bold, percentage in parentheses. n=number of samples analysed.
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A decline in the abundance of MCT1 in the membrane of colo-
nic epithelial cells, and hence in butyrate uptake, would in turn
reduce the availability of intracellular butyrate as a source of energy
and as an important regulator of cellular homeostasis. Indeed, it
has been reported that a reduction in the intracellular concentra-
tion of butyrate may lead to a deregulation of apoptosis and
proliferation in colonic epithelial cells in culture (Singh et al,
1997). A down-regulation of MCT1 would also reduce the avail-
ability of butyrate to act as a cellular metabolite. It has been
shown that colonic carcinomas switch to a more glucogenic pheno-
type and exhibit lower levels of fatty acid and ketone body
utilisation (Holm et al, 1995). It is also documented that the colo-
nic carcinoma cell line, Caco-2, has a high rate of glucose
utilisation and glycogen content (Chantret et al, 1994). Many
tumours, including colonic carcinomas, have been found to express
the high affinity glucose transporter, GLUT1 (Yamamoto et al,
1990). Here, we show that 83.3% of carcinomas displaying signifi-
cantly reduced levels of MCT1 express GLUT1. Notably, all of these
tumours have negligible level of GLUT2, the low affinity glucose
transporter expressed by healthy colonocytes. In cells that normally
express GLUT2, such as hepatocytes and pancreatic islet b cells,
oncogenic transformation induces de novo expression of GLUT1
(Thorens et al, 1988). Transformation is correlated with a decrease
in the expression of GLUT2. GLUT1 has a significantly higher affi-
nity for glucose (Km=1 – 2 mM; Wheeler, 1985) than GLUT2
(Km=15 – 40 mM; Craik and Elliott, 1979), suggesting that the
expression of GLUT1 would allow cells to absorb glucose efficiently
at low extracellular concentrations. In colonic tumours expressing
low levels of MCT1, the induction of GLUT1 and the down-regu-
lation of GLUT2 would enable the cells to take up and utilise
glucose efficiently and ensure their growth and survival in the
absence of their conventional energy source, butyrate.
In summary, our findings show that the colonic butyrate trans-
porter, MCT1, is expressed predominantly on the apical membrane
of surface colonic epithelial cells. Down-regulation of MCT1
expression occurs as an early event in the adenoma – carcinoma
sequence and, in carcinomas, is associated with reduced abundance
of the low affinity glucose transporter GLUT2 and the expression
of the high affinity glucose transporter, GLUT1. These findings
provide new potential markers of neoplastic change in the human
colon. Furthermore, molecular insight into the mechanisms by
which colonic tumours switch their energy source may allow
rationally designed agents to block tumour growth and survival.
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